Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 3Vomiting 1Endometrial Neoplasms 1Cachexia 1Anorexia 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Megestrol × Clear all
NCT00420563 2026-03-16

PAL-ANGI

Centre Oscar Lambret

Phase 2 Completed
88 enrolled
Tumor-Agnostic

Neoplasms

NCT03283488 2023-07-07

Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.

University of Sao Paulo

Phase 2 Completed
52 enrolled

Anorexia, Cachexia, Neoplasms

NCT04430361 2020-06-12

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡